Colorectal gastrointestinal stromal tumor (GIST) is a mesenchymal neoplasm originating from interstitial cells of Cajal (ICC) or their common precursor cells. Approximately 5% of all GISTs occur in the colon and rectum, and this location exhibits more aggressive biological behavior compared to gastric or small bowel GISTs. KIT (CD117) or PDGFRA receptor tyrosine kinase mutations play a key role in pathogenesis. The tumor typically originates from the muscularis propria and demonstrates an exophytic growth pattern, presenting as masses growing outward from the bowel lumen. Colorectal GISTs frequently reach large sizes at diagnosis, containing heterogeneous enhancement, necrosis, and hemorrhagic areas. Dramatic responses can be achieved with imatinib (tyrosine kinase inhibitor) therapy; treatment response is evaluated by size reduction and density decrease on CT (Choi criteria).
Age Range
40-75
Peak Age
60
Gender
Equal
Prevalence
Rare
Colorectal GIST originates from interstitial cells of Cajal (ICC) or common mesenchymal precursor cells. ICCs are pacemaker cells for gastrointestinal motility located within the muscularis propria. Gain-of-function mutations in the KIT proto-oncogene (chromosome 4q11-12) play a key role in pathogenesis; KIT mutations are found in 80-85% of cases and PDGFRA mutations in 5-10%. KIT mutation causes ligand-independent receptor activation, triggering uncontrolled cell proliferation through downstream signaling pathways (PI3K/AKT, RAS/MAPK, JAK/STAT). The tumor's intense vascularity results from neoangiogenesis, producing prominent arterial phase enhancement. Central necrosis in large tumors arises from insufficient blood supply, appearing as heterogeneous enhancement with low-density central areas on imaging. The exophytic growth pattern reflects the tumor's tendency to grow from the muscularis propria toward the serosa — intraluminal growth is rare, so mucosal ulceration is a late finding.
The exophytic growth of GIST from the muscularis propria toward the serosa is a pathognomonic growth pattern where the bowel lumen remains intact. Mucosal ulceration is only seen late in very large tumors. This pattern is the key distinguishing feature from epithelial-origin (intraluminally growing) adenocarcinoma.
Exophytic mass arising from the colon or rectum wall demonstrating prominent heterogeneous enhancement in arterial phase. Peripheral portions represent viable tumor tissue with intense enhancement, while central necrotic/hemorrhagic areas remain hypodense. Enhancement may be more homogeneous in smaller tumors (<5 cm). The mass is usually round-oval shaped with broad-based attachment to the bowel wall.
Report Sentence
An exophytic mass arising from the colon/rectum wall demonstrating prominent heterogeneous arterial phase enhancement with central necrotic hypodense area is observed, and gastrointestinal stromal tumor (GIST) should be considered as the leading diagnosis.
In portal venous phase, peripheral tumor enhancement continues and mildly increases, while central necrotic areas remain hypodense. The heterogeneous enhancement pattern becomes more pronounced in large tumors (>5 cm). The tumor-bowel wall connection can be better evaluated in this phase. The relationship of the exophytic component with surrounding structures (invasion vs. displacement) is optimally assessed in the portal venous phase.
Report Sentence
Continued peripheral enhancement of the mass in portal venous phase with persistent central hypodense necrotic areas is observed; this progressive heterogeneous enhancement pattern is consistent with GIST.
Well-defined soft tissue density mass arising from the bowel wall on non-contrast CT (30-50 HU). Low-density central areas (necrosis/hemorrhage) may be seen in large tumors. Calcification is rare in primary GIST (<5%) but more common in post-treatment GISTs. The tumor-bowel wall connection should be evaluated on non-contrast series — smooth serosal margin of the exophytic component supports GIST.
Report Sentence
A well-defined, soft tissue density exophytic mass arising from the colon/rectum wall is observed on non-contrast CT.
Heterogeneous hyperintense mass on T2-weighted images. Viable tumor tissue shows intermediate-to-high T2 signal, while necrotic/cystic areas appear markedly hyperintense and hemorrhagic areas show variable signal. Fibrotic areas may be hypointense on T2. Fluid-debris levels may be seen in large tumors. The exophytic nature of the tumor and its connection to the bowel wall are optimally evaluated on sagittal/coronal T2 sequences.
Report Sentence
A heterogeneous hyperintense exophytic mass arising from the bowel wall on T2-weighted images is observed, containing necrotic and solid components.
Diffusion restriction in solid components of the tumor on diffusion-weighted imaging (DWI) — hyperintense signal at high b-value (b=800-1000) and low signal on ADC map. Necrotic/cystic areas do not show diffusion restriction (high ADC). The degree of diffusion restriction correlates with mitotic activity and cellularity; marked restriction suggests high-risk GIST.
Report Sentence
Diffusion restriction in the solid components of the mass on DWI consistent with high cellularity is observed, increasing the possibility of high-risk GIST.
Colorectal GISTs show variable FDG avidity on FDG PET-CT. High-risk and large tumors demonstrate prominent FDG uptake (SUVmax typically >5), while low-risk tumors may show mild uptake. PET-CT is more sensitive than CT for early assessment of imatinib treatment response — dramatic decrease in FDG uptake is seen 1-2 weeks after treatment initiation (before size change). No FDG uptake in necrotic areas; intense peripheral viable tumor tissue uptake pattern is characteristic.
Report Sentence
Increased FDG uptake in the solid components of the colorectal mass on PET-CT is observed, consistent with metabolically active GIST.
On T1-weighted images, the tumor shows isointense or mildly hypointense signal relative to muscle. Hemorrhagic areas may show hyperintense signal on T1 (methemoglobin effect). Necrotic areas appear hypointense on T1. On gadolinium-enhanced T1 images, viable tumor tissue shows prominent enhancement while necrotic areas do not enhance — this pattern parallels the heterogeneous enhancement on CT.
Report Sentence
Isointense exophytic mass to muscle on T1-weighted images is observed with prominent enhancement of peripheral viable tumor tissue and non-enhancing central necrotic area on contrast-enhanced series.
Criteria
Size <5 cm and mitotic index <5/50 HPF. Homogeneous enhancement, minimal necrosis. Low recurrence risk even in colorectal location.
Distinct Features
Usually homogeneous enhancement, smooth margins, minimal necrosis. Appears as a small exophytic soft tissue density mass on CT. May show mild diffusion restriction on DWI.
Criteria
Size >5 cm or mitotic index >5/50 HPF (or any size colorectal GIST with mitotic index >5). Marked necrosis, heterogeneous enhancement, high recurrence/metastasis risk.
Distinct Features
Marked heterogeneous enhancement, central necrosis, irregular margins. Colorectal location shows more aggressive course compared to other locations — worse prognosis than gastric GIST at the same size and mitotic index. High risk of liver and peritoneal metastasis.
Criteria
GIST located in the rectum. The majority of colorectal GISTs are rectally located. MRI is the preferred modality for local staging and surgical planning.
Distinct Features
On MRI, relationship with mesorectal fascia, proximity to sphincter complex, and adjacency to pelvic structures are evaluated. High-resolution T2 sequences demonstrate the tumor's relationship with layered structures. Neoadjuvant imatinib may increase the chance of sphincter-preserving surgery in borderline resectable rectal GISTs.
Criteria
GIST lacking KIT and PDGFRA mutations (10-15%). Includes SDH-deficient GIST, NF1-associated GIST, or other rare mutations (BRAF, NTRK). Resistant to imatinib.
Distinct Features
Indistinguishable from standard GIST on imaging. Multifocal involvement may be seen in SDH-deficient and NF1-associated GIST. Lack of response to imatinib (persistent FDG uptake on PET-CT, no size/density change on CT) suggests this subtype.
Distinguishing Feature
Adenocarcinoma shows intraluminal growth, mucosal irregularity, and stricture formation; GIST grows exophytically with usually intact mucosa. Adenocarcinoma typically demonstrates apple-core defect while GIST is a well-defined exophytic mass.
Distinguishing Feature
Lymphoma typically shows aneurysmal dilatation, homogeneous wall thickening, and minimal obstruction; GIST demonstrates exophytic mass and heterogeneous enhancement. Lymphoma may be associated with peritoneal lymphadenopathy; GIST is usually solitary.
Distinguishing Feature
Metastasis typically shows multifocal involvement with known primary malignancy; colorectal GIST is a solitary exophytic mass. Metastasis may coexist with peritoneal carcinomatosis; peritoneal spread in GIST is a late finding.
Distinguishing Feature
Carcinoid tumor typically presents as a small, homogeneously enhancing submucosal nodule; GIST is larger with heterogeneous enhancement. Rectal carcinoids are usually <2 cm and intraluminal; GIST is exophytic and generally larger.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralCT-guided core biopsy or EUS-guided fine needle biopsy is required for colorectal GIST diagnosis — histopathological confirmation and KIT/PDGFRA mutation analysis are mandatory for treatment planning. Surgical resection is the primary treatment; R0 resection is the goal. Adjuvant imatinib (at least 3 years) is recommended due to high recurrence risk in colorectal location. Neoadjuvant imatinib followed by surgery is considered for borderline resectable or large tumors. Treatment response is evaluated by Choi criteria (RECIST is inadequate). Follow-up: CT every 3-6 months (first 3-5 years), then annually. Liver metastasis is the most common distant spread site.
Good response to imatinib (tyrosine kinase inhibitor) therapy. Size (>5 cm) and mitotic index determine malignancy risk. Surgical resection is primary treatment.